BlackRock’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-789,911
| Closed | -$1.18M | – | 5670 |
|
|
2023
Q1 | $1.18M | Sell |
789,911
-962
| -0.1% | -$1.3K | ﹤0.01% | 4278 |
|
|
2022
Q4 | $790K | Sell |
790,873
-234,839
| -23% | -$317K | ﹤0.01% | 4485 |
|
|
2022
Q3 | $1.85M | Sell |
1,025,712
-11,982
| -1% | -$34.7K | ﹤0.01% | 4230 |
|
|
2022
Q2 | $3.01M | Sell |
1,037,694
-1,495,222
| -59% | -$3.69M | ﹤0.01% | 4057 |
|
|
2022
Q1 | $6.99M | Buy |
2,532,916
+131,171
| +5% | +$413K | ﹤0.01% | 3777 |
|
|
2021
Q4 | $11.2M | Sell |
2,401,745
-562,900
| -19% | -$3.52M | ﹤0.01% | 3605 |
|
|
2021
Q3 | $25.2M | Buy |
2,964,645
+27,527
| +0.9% | +$389K | ﹤0.01% | 3129 |
|
|
2021
Q2 | $48.2M | Sell |
2,937,118
-129,518
| -4% | -$2.62M | ﹤0.01% | 2726 |
|
|
2021
Q1 | $67.7M | Buy |
3,066,636
+463,097
| +18% | +$12.6M | ﹤0.01% | 2416 |
|
|
2020
Q4 | $80.5M | Buy |
2,603,539
+496,950
| +24% | +$12.6M | ﹤0.01% | 2204 |
|
|
2020
Q3 | $42.8M | Buy |
2,106,589
+1,012,572
| +93% | +$17.8M | ﹤0.01% | 2391 |
|
|
2020
Q2 | $16.8M | Buy |
1,094,017
+200,089
| +22% | +$2.31M | ﹤0.01% | 2891 |
|
|
2020
Q1 | $6.92M | Buy |
893,928
+3,888
| +0.4% | +$47.6K | ﹤0.01% | 3183 |
|
|
2019
Q4 | $12.7M | Buy |
890,040
+60,221
| +7% | +$931K | ﹤0.01% | 3127 |
|
|
2019
Q3 | $12.5M | Buy |
829,819
+724,230
| +686% | +$11.3M | ﹤0.01% | 3107 |
|
|
2019
Q2 | $1.51M | Buy |
+105,589
| New | +$1.68M | ﹤0.01% | 3876 |
|
BlackRock's TCRR Position: Q2 2023 in Review
BlackRock sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 789,911 shares — an estimated $1.18M sold.
BlackRock first reported a position in TCRR in Q2 2019 and held it in 16 quarters. The position peaked at $80.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- BlackRock reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- BlackRock sold 789,911 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $1.18M.
- BlackRock first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- BlackRock's TCR2 Therapeutics Inc. Common Stock position peaked at $80.5M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.